Department of Internal Medicine II, Martin - Luther University Halle-Wittenberg, Halle (Saale), Germany.
Department of Nephrology & Diabetology, Carl-Thiem Hospital, Cottbus, Thiemstrasse 111, 03048, Cottbus, Germany.
BMC Nephrol. 2020 Sep 10;21(1):393. doi: 10.1186/s12882-020-02032-z.
Hyponatremia is known to be associated with a worse patient outcome in heart failure. In cardiorenal syndrome (CRS), the prognostic role of concomitant hyponatremia is unclear. We sought to evaluate potential risk factors for hyponatremia in patients with CRS presenting with or without hyponatremia on hospital admission.
In a retrospective study, we investigated 262 CRS patients without sepsis admitted to the University Hospital Halle over a course of 4 years. CRS diagnosis was derived from an electronic search of concomitant diagnoses of acute or chronic (NYHA 3-4) heart failure and acute kidney injury (AKIN 1-3) or chronic kidney disease (KDIGO G3-G5). A verification of CRS diagnosis was done based on patient records. Depending on the presence (Na < 135 mmol/L) or absence (Na ≥ 135 mmol/L) of hyponatremia on admission, the CRS patients were analyzed for comorbidities such as diabetes, presence of hypovolemia on admission, need for renal replacement therapy and prognostic factors such as in-hospital and one-year mortality.
Two hundred sixty-two CRS patients were included in this study, thereof, 90 CRS patients (34.4%) with hyponatremia (Na < 135 mmol/L). The diabetes prevalence among CRS patients was high (> 65%) and not related to the serum sodium concentration on admission. In comparison to non-hyponatremic CRS patients, the hyponatremic patients had a lower serum osmolality, hypovolemia was more prevalent (41.1% versus 16.3%, p < 0.001). As possible causes of hypovolemia, diarrhea, a higher number of diuretic drug classes and higher diuretic dosages were found. Hyponatremic and non-hyponatremic CRS patients had a comparable need for renal-replacement therapy (36.7% versus 31.4%) during the hospital stay. However, after discharge, relatively more hyponatremic CRS patients on renal replacement therapy switched to a non-dialysis therapy regimen (50.0% versus 22.2%). Hyponatremic CRS patients showed a trend for a higher in-hospital mortality (15.6% versus 7.6%, p = 0.054), but no difference in the one-year mortality (43.3% versus 40.1%, p = 0.692).
All CRS patients showed a high prevalence of diabetes mellitus and a high one-year mortality. In comparison to non-hyponatremic CRS patients, hyponatremic ones were more likely to have hypovolemia, and had a higher likelihood for temporary renal replacement therapy.
低钠血症与心力衰竭患者的预后较差有关。在心脏肾综合征(CRS)中,同时存在低钠血症的预后作用尚不清楚。我们旨在评估伴有或不伴有入院时低钠血症的 CRS 患者发生低钠血症的潜在危险因素。
在一项回顾性研究中,我们调查了在四年期间入住哈雷大学医院的 262 例无脓毒症的 CRS 患者。CRS 的诊断源自对急性或慢性(NYHA 3-4)心力衰竭和急性肾损伤(AKIN 1-3)或慢性肾脏病(KDIGO G3-G5)的并发诊断的电子搜索。根据患者记录对 CRS 诊断进行了验证。根据入院时存在(Na < 135 mmol/L)或不存在(Na ≥ 135 mmol/L)低钠血症,对 CRS 患者进行了糖尿病等合并症、入院时低血容量的存在、是否需要肾脏替代治疗以及住院和一年死亡率等预后因素的分析。
本研究共纳入 262 例 CRS 患者,其中 90 例 CRS 患者(34.4%)存在低钠血症(Na < 135 mmol/L)。CRS 患者的糖尿病患病率较高(> 65%),与入院时的血清钠浓度无关。与非低钠血症 CRS 患者相比,低钠血症患者的血清渗透压较低,低血容量更为常见(41.1%与 16.3%,p < 0.001)。腹泻、利尿剂药物种类更多和利尿剂剂量更高是低血容量的可能原因。低钠血症和非低钠血症 CRS 患者在住院期间需要肾脏替代治疗的比例相当(36.7%与 31.4%)。然而,出院后,相对更多的低钠血症 CRS 患者在肾脏替代治疗中转为非透析治疗方案(50.0%与 22.2%)。低钠血症 CRS 患者的住院死亡率有升高趋势(15.6%与 7.6%,p = 0.054),但一年死亡率无差异(43.3%与 40.1%,p = 0.692)。
所有 CRS 患者的糖尿病患病率和一年死亡率均较高。与非低钠血症 CRS 患者相比,低钠血症患者更有可能出现低血容量,并且更有可能需要临时肾脏替代治疗。